Abstract
Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19).
Highlights
Since the outbreak of the new coronavirus pneumonia (COVID-19) in December 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it has spread to the whole country
Clinical trials of chloroquine were conducted in hospitals in Beijing and Guangdong province, and the results showed that chloroquine phosphate may be effective in treating COVID-19
Based on the published clinical guidelines and research results, this paper proposes the following pharmaceutical care for the elderly using chloroquine phosphate in the treatment of COVID-19
Summary
Since the outbreak of the new coronavirus pneumonia (COVID-19) in December 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it has spread to the whole country. Oral administration of chloroquine phosphate is the only suggested administration in elderly patients. For elderly patients with a bodyweight of more than 50 kg, chloroquine phosphate 500 mg orally, bid, for 7 days is recommended. According to the Wuhan Institute of Virology, Chinese Academy of Sciences, the lethal dose of chloroquine phosphate in adults is 2-4 g and doses should be closely monitored during the treatment period.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call